The U.S. Food and Drug Administration awarded Roche’s Alzheimer’s disease drug candidate Breakthrough Therapy Designation, bringing the IgG1 antibody gantenerumab closer to finally receiving full FDA approval.
As Merck & Co. and Pfizer Inc. prepare to report clinical trial results for experimental Covid-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.
A World Health Organization (WHO) panel on Sept. 24 recommended the use of Regeneron and Roche’s Covid-19 antibody cocktail for patients at high risk of hospitalizations and those severely ill with no natural antibodies.
The U.S. Food and Drug Administration on Sept. 20 approved South Korean drugmaker Samsung Bioepis Co. Ltd. and Biogen Inc.’s biosimilar rival to Roche Holding AG’s blockbuster eye medicine Lucentis.
Pancreatic cancer has the lowest survival rate of the most common cancers as less than 10 percent of patients survive longer than five years, largely due to most cases being diagnosed at a late stage. A collaboration between NovoCure and Roche hopes to improve those odds.
Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest.
Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.
Racho Jordanov and Rose Lin, the septuagenarian co-founders of Taiwanese biotech company JHL Biotech, were convicted Aug. 26 of conspiring to steal trade secrets related to four Genentech (Roche) blockbuster cancer and cystic-fibrosis drugs. The pair were also found guilty of wire fraud.
Roche Holding AG decided to withdraw the company’s immunotherapy Tecentriq as a treatment for a type of breast cancer in the United States, the drugmaker said on Aug. 26 following a consultation with the Food and Drug Administration.
The UK drug regulator approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, as the nation battles rising hospitalizations due to the more infectious Delta variant.